IS8959A - N3 alkýleraðar bensimíðasól afleiður sem MEK hindrar - Google Patents

N3 alkýleraðar bensimíðasól afleiður sem MEK hindrar

Info

Publication number
IS8959A
IS8959A IS8959A IS8959A IS8959A IS 8959 A IS8959 A IS 8959A IS 8959 A IS8959 A IS 8959A IS 8959 A IS8959 A IS 8959A IS 8959 A IS8959 A IS 8959A
Authority
IS
Iceland
Prior art keywords
benzimidazole derivatives
alkylated benzimidazole
mek
inhibits
mek inhibits
Prior art date
Application number
IS8959A
Other languages
English (en)
Other versions
IS2990B (is
Inventor
Eli M Wallace
Joseph P Lyssikatos
Brian T Hurley
Allison L Marlow
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8959(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of IS8959A publication Critical patent/IS8959A/is
Publication of IS2990B publication Critical patent/IS2990B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IS8959A 2002-03-13 2011-06-16 N3 alkýleraðar bensimíðasól afleiður sem MEK hindrar IS2990B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36400702P 2002-03-13 2002-03-13

Publications (2)

Publication Number Publication Date
IS8959A true IS8959A (is) 2011-06-16
IS2990B IS2990B (is) 2017-12-15

Family

ID=28041856

Family Applications (4)

Application Number Title Priority Date Filing Date
IS7442A IS2748B (is) 2002-03-13 2004-09-09 Útbúnaður til að hagræða fiski í flökunarvél til að flökin verði jafn þykk
IS8959A IS2990B (is) 2002-03-13 2011-06-16 N3 alkýleraðar bensimíðasól afleiður sem MEK hindrar
IS8961A IS2999B (is) 2002-03-13 2011-06-16 N3 alkýleraðar bensimíðasól afleiður sem MEK hindrar
IS8960A IS2998B (is) 2002-03-13 2011-06-16 N3 aklýleraðar bensimíðasól afleiður sem MEK hindrar

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS7442A IS2748B (is) 2002-03-13 2004-09-09 Útbúnaður til að hagræða fiski í flökunarvél til að flökin verði jafn þykk

Family Applications After (2)

Application Number Title Priority Date Filing Date
IS8961A IS2999B (is) 2002-03-13 2011-06-16 N3 alkýleraðar bensimíðasól afleiður sem MEK hindrar
IS8960A IS2998B (is) 2002-03-13 2011-06-16 N3 aklýleraðar bensimíðasól afleiður sem MEK hindrar

Country Status (35)

Country Link
US (11) US20030232869A1 (is)
EP (5) EP1482932B1 (is)
JP (4) JP4093966B2 (is)
KR (3) KR100984595B1 (is)
CN (4) CN100519539C (is)
AR (3) AR038971A1 (is)
AT (1) ATE449605T1 (is)
AU (2) AU2003218157C1 (is)
BE (1) BE2019C510I2 (is)
BR (1) BR122018007328B8 (is)
CA (1) CA2478374C (is)
CL (2) CL2012002381A1 (is)
CY (3) CY1109727T1 (is)
DE (1) DE60330227D1 (is)
DK (4) DK3000810T3 (is)
DO (4) DOP2003000613A (is)
ES (5) ES2635666T3 (is)
FR (1) FR19C1014I2 (is)
HU (2) HUE025767T2 (is)
IL (4) IL163995A0 (is)
IS (4) IS2748B (is)
LT (1) LTC1482932I2 (is)
LU (1) LUC00100I2 (is)
MX (1) MXPA04008893A (is)
NL (1) NL300974I2 (is)
NZ (1) NZ535158A (is)
PA (1) PA8569301A1 (is)
PL (5) PL401637A1 (is)
PT (4) PT1482932E (is)
SG (3) SG148857A1 (is)
SI (4) SI2275102T1 (is)
TW (3) TWI338685B (is)
UA (1) UA77765C2 (is)
WO (1) WO2003077914A1 (is)
ZA (1) ZA200407220B (is)

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL401637A1 (pl) * 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2004054515A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Thrombopoietin mimetics
US20060140872A1 (en) * 2003-02-26 2006-06-29 Kowa Co., Ltd. Novel signaling pathway for the production of inglammatory pain and neuropathy
DE602004023207D1 (de) 2003-07-24 2009-10-29 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
DE602004027932D1 (de) 2003-09-22 2010-08-12 S Bio Pte Ltd Benzimidazolderivate: herstellung und pharmazeutische anwendungen
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2545659C (en) 2003-11-19 2013-06-04 Array Biopharma Inc. Bicyclic inhibitors of mek
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
KR101223914B1 (ko) * 2003-11-21 2013-01-18 어레이 바이오파마 인크. Akt 단백질 키나제 억제제
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
BRPI0518192B8 (pt) 2004-10-20 2021-05-25 Applied Res Systems Ars Holding N V derivados de 3-arilamino piridina, seu uso e seu processo de fabricação, e composição farmacêutica
JP2008521858A (ja) * 2004-12-01 2008-06-26 ラボラトワール セローノ ソシエテ アノニム 過増殖性疾患を処置するための[1,2,4]トリアゾロ[4,3−a]ピリジン誘導体
US7429667B2 (en) * 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
PL2364973T3 (pl) 2005-05-18 2014-12-31 Array Biopharma Inc Heterocykliczne inhibitory MEK i sposoby ich stosowania
CA2612419C (en) * 2005-06-23 2017-06-13 Array Biopharma Inc. Process for preparing benzimidazole compounds
HUE043172T2 (hu) * 2005-06-23 2019-08-28 Array Biopharma Inc SNAr eljárás benzimidazol-származékok elõállítására
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AU2012261703B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
AU2013203939B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
CA2927656C (en) * 2005-10-07 2019-09-24 Exelixis, Inc. Mek inhibitors and methods of their use
US7968108B2 (en) * 2005-10-25 2011-06-28 Metbro Distributing L.P. Hydrogen cyanamide pesticide formulations
US7572460B2 (en) * 2005-10-25 2009-08-11 Rodrigo Rodriguez-Kabana Hydrogen cyanamide pesticide formulations
RU2418790C3 (ru) * 2005-12-21 2022-03-14 Астразенека Аб Новая гидросульфатная соль
EP1966155A1 (en) * 2005-12-21 2008-09-10 AstraZeneca AB Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
CA2534243A1 (fr) 2006-01-25 2007-07-25 Hydro Quebec Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
DE602007009663D1 (de) 2006-04-18 2010-11-18 Ardea Biosciences Inc Pyridonsulfonamide und pyridonsulfamide als mek-hemmer
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101516891B (zh) 2006-07-06 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
ES2372955T3 (es) 2006-07-06 2012-01-30 Array Biopharma, Inc. Ciclopenta[d]pirimidinas como inhibidores de la proteína cinasa akt.
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
ZA200901009B (en) * 2006-08-21 2010-05-26 Genentech Inc Aza-benzothiophenyl compounds and methods of use
US20080085886A1 (en) * 2006-08-21 2008-04-10 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
US7893085B2 (en) * 2006-08-21 2011-02-22 Genentech, Inc Aza-benzothiophenyl compounds and methods of use
US7999006B2 (en) 2006-12-14 2011-08-16 Exelixis, Inc. Methods of using MEK inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
US20100130519A1 (en) * 2007-04-13 2010-05-27 Stephen Robert Wedge Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
US8509487B2 (en) * 2007-04-19 2013-08-13 Avago Technologies General Ip (Singapore) Pte. Ltd. System and method for optically measuring a parameter of an object
US8258152B2 (en) 2007-06-12 2012-09-04 Genentech, Inc. N-substituted azaindoles and methods of use
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101801955B (zh) 2007-07-05 2013-05-08 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
CA2692506C (en) 2007-07-05 2015-11-24 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2702315A1 (en) * 2007-10-15 2009-04-23 Astrazeneca Ab Combination 059
US8022057B2 (en) 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
NZ586802A (en) 2007-12-19 2012-03-30 Genentech Inc Imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives for the treatment of inflammatory diseases
JP5710268B2 (ja) 2007-12-19 2015-04-30 ジェネンテック, インコーポレイテッド 8−アニリノイミダゾピリジン及びその抗ガン及び/又は抗炎症剤としての使用
US8063085B2 (en) 2007-12-20 2011-11-22 Hoffmann-La Roche Inc. Substituted hydantoins
US8486963B2 (en) 2007-12-21 2013-07-16 Genentech, Inc. Azaindolizines and methods of use
MX2010007546A (es) 2008-01-09 2010-09-30 Array Biopharma Inc Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
EP2247578B1 (en) 2008-01-09 2013-05-22 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
WO2009157167A1 (ja) 2008-06-23 2009-12-30 パナソニック株式会社 無線通信基地局装置および参照信号割当方法
CN102137847B (zh) 2008-07-01 2015-06-10 健泰科生物技术公司 作为mek激酶抑制剂的二环杂环
KR20110028376A (ko) * 2008-07-01 2011-03-17 제넨테크, 인크. Mek 키나제 억제제로서의 이소인돌론 유도체 및 사용 방법
PL2307376T3 (pl) 2008-08-04 2016-04-29 Merck Patent Gmbh Nowe związki fenyloaminoizonikotynoamidowe
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资(香港)有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
US8470819B2 (en) * 2008-11-03 2013-06-25 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
US8993630B2 (en) 2008-11-10 2015-03-31 Bayer Intellectual Property Gmbh Substituted sulphonamido phenoxybenzamides
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US20120263714A1 (en) 2009-10-21 2012-10-18 Bayer Intellectual Property Gmbh Substituted halophenoxybenzamide derivatives
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
MX2012015100A (es) 2010-06-25 2013-05-01 Novartis Ag Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
ES2575995T3 (es) 2010-08-05 2016-07-04 Case Western Reserve University Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal
NZ608069A (en) 2010-10-06 2014-06-27 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
JP2013542214A (ja) 2010-10-29 2013-11-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換フェノキシピリジン類
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
KR102482184B1 (ko) 2010-12-22 2022-12-28 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
EP2655375B1 (fr) 2010-12-23 2014-12-03 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
CN112915092A (zh) 2011-04-01 2021-06-08 基因泰克公司 Akt抑制剂化合物和阿比特龙的组合及使用方法
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US20140228418A1 (en) * 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US9833439B2 (en) 2011-05-25 2017-12-05 Universite Paris Descartes ERK inhibitors for use in treating spinal muscular atrophy
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
AU2012290121B2 (en) * 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
JP6058009B2 (ja) * 2011-08-31 2017-01-11 ノバルティス アーゲー Pi3k−およびmek−阻害剤の相乗的な組合せ
JP2014528928A (ja) * 2011-09-01 2014-10-30 ノバルティス アーゲー ヌーナン症候群の治療のための有機化合物の使用
EP2570127A1 (en) 2011-09-16 2013-03-20 Sanofi Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
PH12014500809A1 (en) 2011-10-14 2014-05-26 Array Biopharma Inc Polymorphs of arry-380, a slective herb2 inhibitor and pharmaceutical compositions containing them
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とhsp90阻害剤の組合せ療法
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
HK1205758A1 (en) 2012-01-09 2015-12-24 Novartis Ag Rnai agents to treat beta-catenin related diseases
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CN103204822B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
KR102088469B1 (ko) * 2012-03-20 2020-03-17 노파르티스 아게 Mek 억제제 및 igf1r 억제제의 병용 요법
CN104350415B (zh) 2012-04-09 2018-01-16 思维奇材料公司 转换材料,及其组合物和制造方法
JP6463673B2 (ja) 2012-05-29 2019-02-06 スイッチ マテリアルズ インコーポレイテッドSwitch Materials Inc. 可変透過率層を含む光学フィルタ
US20150267258A1 (en) 2012-05-31 2015-09-24 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
HUE044789T2 (hu) 2012-08-17 2019-11-28 Hoffmann La Roche Cobimetinib és vemurafenib beadását magukban foglaló kombinált terápiák melanóma kezelésére
SG10201703682YA (en) 2012-10-02 2017-06-29 Epitherapeutics Aps Inhibitors of histone demethylases
PE20151494A1 (es) 2012-10-12 2015-11-06 Exelixis Inc Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
EP2909181B1 (en) 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
LT3702351T (lt) * 2012-10-19 2024-01-10 Array Biopharma, Inc. Kompozicijos, apimančios mek inhibitorių
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
CA2892578C (en) * 2012-11-29 2021-01-12 Novartis Ag Pharmaceutical combinations of a pck inhibitor and a mek inhibitor for use in treatment of cancer
ES2676177T3 (es) 2012-12-20 2018-07-17 Novartis Ag Una combinación farmacéutica que comprende binimetinib
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
US20140242595A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
EP2963114B1 (en) 2013-02-27 2018-12-12 Daiichi Sankyo Company, Limited Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway
US9650339B2 (en) 2013-02-27 2017-05-16 Gilead Sciences, Inc. Inhibitors of histone demethylases
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Jak2 및 alk2 억제제 및 이들의 사용 방법
HUE055072T2 (hu) 2013-03-21 2021-10-28 Array Biopharma Inc B-Raf gátlót és második gátlószert tartalmazó kombinációs terápia
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
PL3083567T3 (pl) 2013-12-19 2018-08-31 Idorsia Pharmaceuticals Ltd Przeciwbakteryjne pochodne 1h-indazolu i 1h-indolu
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
CN104788365B (zh) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 异烟酰胺衍生物、其制备方法及应用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN120536341A (zh) 2014-03-04 2025-08-26 菲特治疗公司 改良的重编程方法和细胞培养平台
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
EP3126345A1 (en) 2014-03-31 2017-02-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
US20170107486A1 (en) 2014-04-21 2017-04-20 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
JP2017515906A (ja) 2014-05-16 2017-06-15 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 抗菌性キナゾロン−4(3h)−オン誘導体
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
AU2015289672A1 (en) 2014-07-15 2017-03-02 Genentech, Inc. Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors
KR20170040805A (ko) 2014-08-27 2017-04-13 길리애드 사이언시즈, 인코포레이티드 히스톤 데메틸라제를 억제하기 위한 화합물 및 방법
BR112017004826A2 (pt) 2014-09-13 2017-12-12 Novartis Ag terapias de combinação de inibidores de alk
CN107106687A (zh) 2014-10-03 2017-08-29 诺华股份有限公司 组合治疗
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR102513870B1 (ko) 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
MX375970B (es) 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
SG10202101358XA (en) 2015-01-26 2021-03-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
BR112017018908A2 (pt) 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
KR20170129757A (ko) 2015-03-25 2017-11-27 노파르티스 아게 Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
JP6878405B2 (ja) 2015-07-29 2021-05-26 ノバルティス アーゲー Pd−1に対する抗体分子を含む組み合わせ治療
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
AU2016314082B2 (en) 2015-08-28 2019-07-25 Novartis Ag Mdm2 inhibitors and combinations thereof
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
SG10202111851YA (en) 2015-10-16 2021-12-30 Fate Therapeutics Inc Platform for the Induction & Maintenance of Ground State Pluripotency
CA3004117A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
ES2953925T3 (es) 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
EP3371301A4 (en) 2015-11-04 2019-06-26 Fate Therapeutics, Inc. METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
TWI782906B (zh) 2016-03-04 2022-11-11 日商大鵬藥品工業股份有限公司 惡性腫瘤治療用製劑及組合物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
CR20190002A (es) 2016-06-03 2019-06-10 Zhu Alexander Cao Combinaciones farmacéuticas
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
KR102519922B1 (ko) 2016-06-20 2023-04-11 노파르티스 아게 트리아졸로피리미딘 화합물의 결정질 형태
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018065924A1 (en) * 2016-10-04 2018-04-12 Sun Pharmaceutical Industries Limited Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN108084078B (zh) * 2016-11-24 2021-07-30 中山大学 一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
EP3548049A4 (en) 2016-12-05 2020-07-22 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
EP3372624A1 (en) 2017-03-06 2018-09-12 Henkel AG & Co. KGaA One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3712133A4 (en) * 2017-11-14 2021-05-12 Shenzhen TargetRx, Inc. SUBSTITUTE BENZIMIDAZOLE COMPOUND AND COMPOSITION CONSISTING OF IT
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MX2020009762A (es) 2018-03-19 2021-01-08 Taiho Pharmaceutical Co Ltd Composicion farmaceutica que incluye alquil sulfato de sodio.
US11013741B1 (en) 2018-04-05 2021-05-25 Sumitomo Dainippon Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
SG11202011633SA (en) 2018-05-24 2020-12-30 Janssen Biotech Inc Psma binding agents and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
EP4541379A3 (en) 2018-07-25 2025-07-23 Advanced Accelerator Applications S.A. Stable, concentrated radionuclide complex solutions
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
RS64238B1 (sr) 2018-08-17 2023-06-30 Novartis Ag Jedinjenja i sastavi uree kao inhibitori smarca2/brm-atpaze
JP7358484B2 (ja) 2018-09-25 2023-10-10 アドヴァンスド・アクセラレーター・アプリケーションズ・(イタリー)・エッセエッレエッレ 併用療法
EP3883567B8 (en) 2018-11-20 2025-07-02 NFlection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
US11572344B2 (en) 2018-11-20 2023-02-07 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
US20240245670A1 (en) 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ, インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
CA3133460A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020212832A1 (en) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Process of preparation of benzimidazole compounds
US11591395B2 (en) 2019-04-19 2023-02-28 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和失調症之化合物
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
AU2020355837B2 (en) 2019-09-26 2025-10-02 Novartis Ag AZA-quinoline compounds and uses thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021116901A1 (en) * 2019-12-09 2021-06-17 Biocon Limited Forms of binimetinib and process for preparation thereof
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230158152A1 (en) * 2020-03-17 2023-05-25 Medshine Discovery Inc. Proteolysis regulator and method for using same
TW202200146A (zh) 2020-04-10 2022-01-01 日商大鵬藥品工業股份有限公司 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法
PE20231651A1 (es) 2020-06-09 2023-10-17 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
EP4225307A1 (en) 2020-10-05 2023-08-16 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk﹘5抑制劑和彼之用途
CN112759552A (zh) * 2020-12-31 2021-05-07 武汉九州钰民医药科技有限公司 司美替尼的合成方法
CN112679438A (zh) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 制备司美替尼的方法
US12141240B2 (en) 2021-01-20 2024-11-12 Rutgers, The State University Of New Jersey Method of calibration using master calibration function
WO2022159600A1 (en) * 2021-01-21 2022-07-28 Nflection Therapeutics, Inc. Processes for preparing pyrrolopyridine-aniline compounds
MX2023008909A (es) 2021-01-28 2023-10-23 Janssen Biotech Inc Proteínas de unión a psma y usos de estas.
US20250179063A2 (en) 2021-02-02 2025-06-05 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
JP2024511373A (ja) 2021-03-18 2024-03-13 ノバルティス アーゲー がんのためのバイオマーカーおよびその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
EP4322953A4 (en) * 2021-04-15 2025-01-22 Ideaya Biosciences, Inc. COMBINATION THERAPY WITH A PKC INHIBITOR AND A MEK INHIBITOR
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN117642166A (zh) 2021-06-09 2024-03-01 中外制药株式会社 用于癌症治疗的组合疗法
WO2022262699A1 (zh) * 2021-06-17 2022-12-22 深圳市塔吉瑞生物医药有限公司 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
TW202317546A (zh) 2021-07-09 2023-05-01 美商普萊克斯姆公司 調節ikzf2之芳基化合物及醫藥組合物
MX2024005107A (es) 2021-11-04 2024-05-14 Hoffmann La Roche Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
WO2023084489A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
IL317102A (en) 2022-05-20 2025-01-01 Novartis Ag EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of using them
EP4525926A1 (en) 2022-05-20 2025-03-26 Novartis AG Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023238000A1 (en) * 2022-06-06 2023-12-14 Glenmark Life Sciences Limited Process for preparation of selumetinib and salts thereof
WO2024105144A1 (en) 2022-11-18 2024-05-23 F. Hoffmann-La Roche Ag Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
AU2024234194A1 (en) 2023-03-10 2025-08-07 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
FR3159741A1 (fr) 2024-03-04 2025-09-05 Pierre Fabre Medicament Formulation topique comprenant du binimetinib
PL451048A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451046A1 (pl) * 2025-01-27 2025-06-09 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451049A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451050A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451047A1 (pl) * 2025-01-27 2025-08-18 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451045A1 (pl) * 2025-01-27 2025-06-09 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980001113A1 (en) 1978-11-20 1980-05-29 Braun Ag Time-keeper in particular quartz controlled clock
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
US5218356A (en) * 1991-05-31 1993-06-08 Guenther Knapp Wireless indoor data relay system
US5216003A (en) * 1992-01-02 1993-06-01 G. D. Searle & Co. Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
EP0710654A4 (en) 1993-07-23 1996-08-28 Green Cross Corp TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
PE27997A1 (es) 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
US5520187A (en) * 1994-11-25 1996-05-28 General Electric Company Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
US5972980A (en) * 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
GB9600344D0 (en) * 1996-01-09 1996-03-13 Lilly Co Eli Benzimidzolyl neuropeptide y receptor antagonists
PT923585E (pt) 1996-07-18 2002-08-30 Pfizer Inibidores a base de fosfinato de metaloproteases de matriz
SK21499A3 (en) 1996-08-23 2000-05-16 Pfizer Arylsulfonylamino hydroxamic acid derivatives
CA2277100C (en) 1997-01-06 2005-11-22 Pfizer Inc. Cyclic sulfone derivatives
PL335027A1 (en) 1997-02-03 2000-03-27 Pfizer Prod Inc Derivatives of arylsulphonylamino hydroxamic acid
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
JP3710489B2 (ja) 1997-02-11 2005-10-26 ファイザー・インク アリールスルホニルヒドロキサム酸誘導体
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
HUP0003731A3 (en) 1997-07-01 2002-11-28 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
DE69836378T2 (de) 1997-07-01 2007-10-11 Warner-Lambert Co. Llc Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6534503B1 (en) * 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
HUP0104933A3 (en) 1999-01-07 2003-12-29 Warner Lambert Co Antiviral method using mek inhibitors
US6696440B1 (en) 1999-01-07 2004-02-24 Warner-Lambert Company Treatment of asthma with MEK inhibitors
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
EP1144371B1 (en) 1999-01-13 2005-11-09 Warner-Lambert Company Llc Benzenesulphonamide derivatives and their use as mek inhibitors
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
NZ513433A (en) * 1999-01-13 2003-05-30 Warner Lambert Co Benzoheterocycles, their use as MEK inhibitors and use in treating proliferative diseases such as cancer
PL348870A1 (en) 1999-01-13 2002-06-17 Warner Lambert Co 1-heterocycle substituted diarylamines
DE69928697T2 (de) 1999-01-13 2006-06-22 Warner-Lambert Co. Llc Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
US7030119B1 (en) * 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
JP2003504399A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Mek阻害剤を用いる慢性疼痛の治療方法
JP2003504398A (ja) * 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Mek阻害剤を用いた慢性疼痛の治療方法
DK1202724T3 (da) 1999-07-16 2004-01-26 Warner Lambert Co Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
EP1202726A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
EP1339702A1 (en) * 2000-03-15 2003-09-03 Warner-Lambert Company 5-amide substituted diarylamines as mek inhibitors
WO2001068619A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
NZ524120A (en) * 2000-07-19 2005-08-26 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
CZ2003477A3 (cs) 2000-08-25 2003-10-15 Warner - Lambert Company Llc Způsob přípravy N-aryl-anthranilových kyselin a jejich derivátů
JP2004514718A (ja) * 2000-11-02 2004-05-20 アストラゼネカ アクチボラグ 抗癌剤としての置換キノリン類
AU2002221239A1 (en) * 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic benzimidazole compounds
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
WO2002072548A2 (en) * 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
US20040039208A1 (en) 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
WO2003024899A2 (en) * 2001-09-17 2003-03-27 Bristol-Myers Squibb Company CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
AU2002348791A1 (en) 2001-12-21 2003-07-09 Warner-Lambert Company Llc Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof
WO2003062191A1 (en) * 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PL401637A1 (pl) * 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
UA76837C2 (uk) * 2002-03-13 2006-09-15 Еррей Байофарма Інк. N3 алкіловані похідні бензімідазолу як інгібітори мек
DE10238002A1 (de) * 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
NZ538401A (en) * 2002-09-06 2008-03-28 Janssen Pharmaceutica Nv (1H-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders
US20040127395A1 (en) * 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
DE602004023207D1 (de) 2003-07-24 2009-10-29 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
DE102005032379A1 (de) 2005-07-08 2007-01-11 Conti Temic Microelectronic Gmbh Zugangskontrollsystem für ein Kraftfahrzeug
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
ES2676177T3 (es) 2012-12-20 2018-07-17 Novartis Ag Una combinación farmacéutica que comprende binimetinib

Also Published As

Publication number Publication date
SG148857A1 (en) 2009-01-29
DK2130537T3 (da) 2013-02-18
CN101486682B (zh) 2013-08-14
US8193230B2 (en) 2012-06-05
CY1119136T1 (el) 2018-02-14
ES2407849T3 (es) 2013-06-14
AU2003218157A1 (en) 2003-09-29
CA2478374A1 (en) 2003-09-25
CN101633644A (zh) 2010-01-27
DOP2011000110A (es) 2011-11-30
US8003805B2 (en) 2011-08-23
CY2019012I1 (el) 2020-05-29
WO2003077914A1 (en) 2003-09-25
US20100261718A1 (en) 2010-10-14
JP2012224649A (ja) 2012-11-15
US20080171778A1 (en) 2008-07-17
DOP2013000023A (es) 2013-06-30
CN101633645A (zh) 2010-01-27
DOP2011000109A (es) 2011-11-30
AU2003218157C1 (en) 2011-11-24
KR20100040760A (ko) 2010-04-20
TWI350285B (en) 2011-10-11
SI3000810T1 (sl) 2017-10-30
EP2130537B1 (en) 2012-11-14
RU2307831C9 (ru) 2008-06-10
NZ535158A (en) 2007-06-29
DE60330227D1 (de) 2010-01-07
EP2130536A1 (en) 2009-12-09
US8193231B2 (en) 2012-06-05
IS2999B (is) 2018-06-15
PL233493B1 (pl) 2019-10-31
EP1482932A4 (en) 2006-04-05
US7973170B2 (en) 2011-07-05
PA8569301A1 (es) 2004-10-08
KR100984573B1 (ko) 2010-09-30
ATE449605T1 (de) 2009-12-15
IS7442A (is) 2004-09-09
CY2019012I2 (el) 2020-05-29
CL2012002381A1 (es) 2012-11-05
JP5498546B2 (ja) 2014-05-21
NL300974I2 (nl) 2022-04-06
IS2990B (is) 2017-12-15
IS2748B (is) 2011-08-15
US20110158971A1 (en) 2011-06-30
EP3000810B1 (en) 2017-07-19
TWI343377B (en) 2011-06-11
JP2008019277A (ja) 2008-01-31
PL401636A1 (pl) 2013-05-27
US20100261717A1 (en) 2010-10-14
US20100267793A1 (en) 2010-10-21
AR090143A2 (es) 2014-10-22
SG2013013339A (en) 2014-12-30
PT2130537E (pt) 2012-12-20
SI2130537T1 (sl) 2013-01-31
CN1652776A (zh) 2005-08-10
KR20040094786A (ko) 2004-11-10
US7777050B2 (en) 2010-08-17
US7576114B2 (en) 2009-08-18
JP5102642B2 (ja) 2012-12-19
PL401635A1 (pl) 2013-05-27
CN101486682A (zh) 2009-07-22
ZA200407220B (en) 2007-05-30
US8193229B2 (en) 2012-06-05
HK1153139A1 (en) 2012-03-23
LTC1482932I2 (lt) 2020-04-27
SI1482932T1 (sl) 2010-02-26
RU2004127926A (ru) 2005-06-27
FR19C1014I1 (fr) 2019-04-19
UA77765C2 (en) 2007-01-15
SG194238A1 (en) 2013-11-29
PT3000810T (pt) 2017-10-25
IS8961A (is) 2011-06-16
KR100984595B1 (ko) 2010-09-30
DK3000810T3 (en) 2017-10-16
PL233177B1 (pl) 2019-09-30
US8178693B2 (en) 2012-05-15
TW200407129A (en) 2004-05-16
US7425637B2 (en) 2008-09-16
ES2635666T3 (es) 2017-10-04
CN100519539C (zh) 2009-07-29
SI2275102T1 (sl) 2015-12-31
EP1482932B1 (en) 2009-11-25
PL377628A1 (pl) 2006-02-06
US20100260714A1 (en) 2010-10-14
CY1109727T1 (el) 2014-09-10
ES2335276T3 (es) 2010-03-24
AR090144A2 (es) 2014-10-22
IL204419A (en) 2012-12-31
BR122018007328B8 (pt) 2021-05-25
LUC00100I2 (is) 2020-01-23
DK1482932T3 (da) 2010-02-01
IL204420A0 (en) 2011-07-31
CN101633645B (zh) 2011-06-22
BE2019C510I2 (is) 2022-05-19
MXPA04008893A (es) 2005-06-20
HUE025767T2 (en) 2016-05-30
IL163995A0 (en) 2005-12-18
AR038971A1 (es) 2005-02-02
US20080177082A1 (en) 2008-07-24
LTPA2019007I1 (lt) 2019-03-25
IL163995A (en) 2010-11-30
JP4093966B2 (ja) 2008-06-04
PL401637A1 (pl) 2013-05-27
HK1141976A1 (en) 2010-11-26
PL401638A1 (pl) 2013-05-27
HUS1900011I1 (hu) 2019-04-29
TW201031641A (en) 2010-09-01
EP2275102A1 (en) 2011-01-19
LUC00100I1 (is) 2019-02-13
HK1070823A1 (en) 2005-06-30
US20050143438A1 (en) 2005-06-30
AU2009222613A1 (en) 2009-10-29
EP1482932A1 (en) 2004-12-08
EP2275102B1 (en) 2015-07-29
JP2008163034A (ja) 2008-07-17
DOP2003000613A (es) 2003-09-30
PT1482932E (pt) 2010-01-12
DK2275102T3 (en) 2015-11-02
TWI338685B (en) 2011-03-11
FR19C1014I2 (fr) 2020-03-13
CN101633644B (zh) 2012-05-09
CA2478374C (en) 2009-01-06
AU2009222613B2 (en) 2011-06-16
US8513293B2 (en) 2013-08-20
IS8960A (is) 2011-06-16
BR122018007328B1 (pt) 2020-03-03
US20120277277A1 (en) 2012-11-01
AU2003218157B2 (en) 2009-07-09
US20100267710A1 (en) 2010-10-21
ES2549159T3 (es) 2015-10-23
EP2130536B1 (en) 2013-05-08
EP3000810A1 (en) 2016-03-30
KR100984613B1 (ko) 2010-09-30
RU2307831C2 (ru) 2007-10-10
ES2394347T3 (es) 2013-01-30
KR20100040759A (ko) 2010-04-20
IL204420A (en) 2012-12-31
PT2275102E (pt) 2015-10-27
IS2998B (is) 2018-06-15
US20030232869A1 (en) 2003-12-18
PL230179B1 (pl) 2018-09-28
CL2012002380A1 (es) 2012-11-05
JP2005530709A (ja) 2005-10-13
IL204419A0 (en) 2011-07-31
EP2130537A1 (en) 2009-12-09
TW201031642A (en) 2010-09-01

Similar Documents

Publication Publication Date Title
IS2990B (is) N3 alkýleraðar bensimíðasól afleiður sem MEK hindrar
IS8384A (is) Alkýleraðar bensímídasólafleiður sem MEK-hindrar
IL163996A0 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
IS7667A (is) Nýjar bensimídazólafleiður
IS7660A (is) Nýjar bensóímídasólafleiður nytsamlegar sem andviðkomumiðlar
ATE386518T1 (de) Benzimidazolderivate
DE60309964D1 (de) Inverter
DE50302985D1 (de) Kraftmesslager
DE60331411D1 (de) Axialgleitlager
DE50306063D1 (de) Abgasnachbehandlungsanordnung
DE10257096B4 (de) Umrichter
FI20020763A7 (fi) Kompraattoripiiri
DE60230770D1 (de) Verbesserte Speicheranordnung
HK1070586A (en) N3 alkylated benzimidazole derivatives as mek inhibitors
IS8446A (is) Staðgengin bensimidasól-, benstríasól- og bensimidasólon-o-glúkósíð
UA7712S (uk) Затвор
KR200309652Y1 (ko) 통풍 양말
UA7131S (uk) Рушникова сушарка